Psoriasis patients at high risk of diabetes

August 27, 2012

Munich, Germany - Patients with psoriasis are at high risk of new-onset diabetes mellitus, according to research presented at ESC Congress 2012. The findings were presented at the press conference by Dr Ole Ahlehoff from Copenhagen University Hospital, Gentofte, Denmark and at the scientific session by Usman KHALID.

Psoriasis is a common chronic inflammatory disease that affects approximately 125 million people worldwide. A new study of the entire Danish population confirms previous reports of increased risk of diabetes mellitus in patients with psoriasis and shows that risk increases with severity of psoriasis.

Psoriasis, atherosclerosis, and early steps in the development of diabetes mellitus are characterised by chronic inflammation, i.e. a chronic state of alert. "This chronic state of alert may explain the increased risk of cardiovascular diseases and diabetes mellitus seen in these patients," said Dr Ahlehoff.

The study comprised more than 4 million people, including approximately 50,000 patients with psoriasis, who were followed for 13 years.

The overall rates of new-onset diabetes mellitus per 1,000 observational years were 3.67 (CI=3.65-3.69) in the reference population who did not have psoriasis, 6.93 (CI=6.63-7.25) for patients with mild psoriasis and 9.65 (CI=8.68-10.73) for patients with severe psoriasis.

The risk of new-onset diabetes mellitus was increased in all patients with psoriasis compared to people who did not have psoriasis. Risk increased with the severity of psoriasis. Compared to people without psoriasis, patients with mild psoriasis were 1.5 times more likely to acquire new-onset diabetes mellitus [rate ratio (RR)=1.49; CI=1.43-1.56] and patients with severe psoriasis were more than twice as likely [RR=2.13; CI=1.91-2.37].

The results remained significant after adjustment for potential confounders, including age, sex, socioeconomic status, use of medication, and comorbidity.

Dr Ahlehoff said: "The major conclusion of the study was that psoriasis was associated with increased risk of diabetes mellitus and the risk was highest in patients with severe psoriasis."

"The results add to current evidence of increased risk of cardiovascular and metabolic disease in patients with psoriasis," he added. "More needs to be done to increase awareness in this large group of patients on what steps they can take to decrease their risk factors for cardiovascular disease."

Dr Ahlehoff continued: "Studies are urgently required to examine the impact of aggressive psoriasis treatment on cardiometabolic outcomes."
-end-
Notes to editors

Please note that picture and CV from the author, abstract, picture and CV from spokesperson can be found here.

About the European Society of Cardiology www.escardio.org

The European Society of Cardiology (ESC) represents more than 75,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.About ESC Congress 2012

The ESC Congress is currently the world's premier conference on the science, management and prevention of cardiovascular disease. ESC Congress 2012 takes place 25-29 August at the Messe München in Munich. The scientific programme is available at: http://spo.escardio.org/Welcome.aspx?eevtid=54

More information is available from the ESC Press Office at press@escardio.org.

European Society of Cardiology

Related Psoriasis Articles from Brightsurf:

Most psoriasis patients taking immunosuppressants survive COVID-19
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19.

Getting under the skin of psoriasis
Psoriasis afflicts millions of people worldwide, but treatments are limited to small molecules like steroids, which can cause skin thinning and lose their effectiveness over time.

Psoriasis patients' mental health is more than skin-deep
A new study from Umeå University, Sweden, shows that other somatic diseases have even more impact on patients' mental health than their skin symptoms, highlighting the importance of holistic patient care.

Psoriasis: Towards a novel therapeutic approach
Researchers at the Université libre de Bruxelles (ULB) and the Department of Dermatology of the Erasme hospital uncover the importance of VEGFA signaling in the epidermis to mediate psoriasis development.

Insights into psoriasis suggest a new treatment target
Investigators from Brigham and Women's Hospital and the Harvard Stem Cell Institute have uncovered a novel pathway that may explain why skin thickens in psoriasis and suggests new strategies for developing therapies for the condition.

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

Study: Some biologic treatments for psoriasis may be safer for patients
In the largest study of its kind, Erica D. Dommasch, M.D., M.P.H., a dermatologist in the Department of Dermatology at BIDMC, and colleagues found a decreased risk of infection in patients with psoriasis using some of the newer, more targeted medications compared to those taking methotrexate, a drug widely used since the 1960s as a first line treatment for moderate-to-severe psoriasis.

Higher weight increases risk of psoriasis
The higher a person's BMI, the greater the chance of getting psoriasis.

Lipid that aids normal skin turnover may help psoriasis
Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in the Journal of Investigative Dermatology.

New insight into the mechanism of the drug against sclerosis and psoriasis
A multidisciplinary research team at Aarhus University has provided fundamental new insight into the mechanism of the medical drug dimethyl fumarate, which is the active component of important treatments for multiple sclerosis and psoriasis.

Read More: Psoriasis News and Psoriasis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.